Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Treasury Shares (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Treasury Shares for 15 consecutive years, with $5.6 million as the latest value for Q4 2025.

  • For Q4 2025, Treasury Shares fell 48.79% year-over-year to $5.6 million; the TTM value through Dec 2025 reached $5.6 million, down 48.79%, while the annual FY2025 figure was $5.6 million, 48.79% down from the prior year.
  • Treasury Shares hit $5.6 million in Q4 2025 for Sangamo Therapeutics, down from $11.0 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $11.0 million in Q4 2024 and bottomed at $3.1 million in Q4 2021.
  • Average Treasury Shares over 5 years is $6.2 million, with a median of $5.6 million recorded in 2025.
  • Year-over-year, Treasury Shares skyrocketed 82.11% in 2024 and then crashed 48.79% in 2025.
  • Sangamo Therapeutics' Treasury Shares stood at $3.1 million in 2021, then soared by 67.02% to $5.2 million in 2022, then increased by 15.43% to $6.1 million in 2023, then surged by 82.11% to $11.0 million in 2024, then crashed by 48.79% to $5.6 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $5.6 million, $11.0 million, and $6.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.